On Wednesday, Pfizer Inc. (NYSE:PFE) reported first-quarter adjusted EPS of $0.82, down 33% year over year, beating the consensus of $0.54. The company witnesses a significant decrease in Comirnaty and Paxlovid revenues globally and an unfavorable impact of foreign exchange of $107 million, or 1%.  The U.S. drugmaker reported sales of $14.9 billion, down 20%, beating the consensus of $14.2 billion. Excluding contributions from Comirnaty and Paxlovid, revenues totaled $12.5 billion, an increase of $1.2 billion, or 11% Y/Y operationally. First-quarter 2024 Comirnaty revenues of $354 million declined 88%, primarily driven by lower contractual deliveries and demand in international markets as well as lower U.S. volumes, reflecting the anticipated seasonality of demand for vaccinations and as certain markets, including the U.S., transition to traditional ...